Related references
Note: Only part of the references are listed.Clinical Impact of Residual C-Peptide Secretion in Type 1 Diabetes on Glycemia and Microvascular Complications
Anita Jeyam et al.
DIABETES CARE (2021)
Residual beta cell function in long-term type 1 diabetes associates with reduced incidence of hypoglycemia
Rose A. Gubitosi-Klug et al.
JOURNAL OF CLINICAL INVESTIGATION (2021)
Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial
Matthias von Herrath et al.
LANCET DIABETES & ENDOCRINOLOGY (2021)
Transplant Options for Patients With Diabetes and Advanced Kidney Disease: A Review
Aleksandra Kukla et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2021)
Preserved C-peptide secretion is associated with fewer low-glucose events and lower glucose variability on flash glucose monitoring in adults with type 1 diabetes
Fraser W. Gibb et al.
DIABETOLOGIA (2020)
C-Peptide Levels in Subjects Followed Longitudinally Before and After Type 1 Diabetes Diagnosis in TrialNet
Magdalena M. Bogun et al.
DIABETES CARE (2020)
Six Months of Hybrid Closed-Loop Versus Manual Insulin Delivery With Fingerprick Blood Glucose Monitoring in Adults With Type 1 Diabetes: A Randomized, Controlled Trial
Sybil A. McAuley et al.
DIABETES CARE (2020)
Indications for islet or pancreatic transplantation: Statement of the TREPID working group on behalf of the Societe francophone du diabete (SFD), Societe francaise d'endocrinologie (SFE), Societe francophone de transplantation (SFT) and Societe francaise de nephrologie - dialyse - transplantation (SFNDT)
A. Wojtusciszyn et al.
DIABETES & METABOLISM (2019)
Persistent C-peptide is associated with reduced hypoglycaemia but not HbA1c in adults with longstanding Type 1 diabetes: evidence for lack of intensive treatment in UK clinical practice?
S. M. Marren et al.
DIABETIC MEDICINE (2019)
Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range
Tadej Battelino et al.
DIABETES CARE (2019)
Ten-Year Outcome of Islet Alone or Islet After Kidney Transplantation in Type 1 Diabetes: A Prospective Parallel-Arm Cohort Study
Marie-Christine Vantyghem et al.
DIABETES CARE (2019)
Advances in β-cell replacement therapy for the treatment of type 1 diabetes
Marie-Christine Vantyghem et al.
LANCET (2019)
Closed-loop insulin delivery in adults with type 1 diabetes in real-life conditions: a 12-week multicentre, open-label randomised controlled crossover trial
Pierre-Yves Benhamou et al.
LANCET DIGITAL HEALTH (2019)
Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial
Martin Tauschmann et al.
LANCET (2018)
Day-and-night glycaemic control with closed-loop insulin delivery versus conventional insulin pump therapy in free-living adults with well controlled type 1 diabetes: an open-label, randomised, crossover study
Lia Bally et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Evidence-Informed Clinical Practice Recommendations for Treatment of Type 1 Diabetes Complicated by Problematic Hypoglycemia
Pratik Choudhary et al.
DIABETES CARE (2015)
Demonstration of an Intrinsic Relationship Between Endogenous C-Peptide Concentration and Determinants of Glycemic Control in Type 1 Diabetes Following Islet Transplantation
Augustin M. Brooks et al.
DIABETES CARE (2015)
Impact of C-Peptide Preservation on Metabolic and Clinical Outcomes in the Diabetes Control and Complications Trial
John M. Lachin et al.
DIABETES (2014)
Continuous Glucose Monitoring after Islet Transplantation in Type 1 Diabetes: An Excellent Graft Function (β-Score Greater Than 7) Is Required to Abrogate Hyperglycemia, Whereas a Minimal Function Is Necessary to Suppress Severe Hypoglycemia (β-Score Greater Than 3)
Marie-Christine Vantyghem et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Share Paper
